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Abstract
Background and Aims Previous studies demonstrated that
toll-like receptors 4 and 2 (TLR-4 and TLR-2), which are
expressed on liver-resident Kupffer, hepatic stellate cells,
and circulating monocytes, play a role in nonalcoholic fatty
liver disease. Lecinoxoids are oxidized phospholipids that
antagonize TLR-2- and TLR-4-mediated activation of
innate immune cells and inhibit monocyte migration. In
this study, we tested the effect of two functionally different
lecinoxoids on the development of nonalcoholic steato-
hepatitis and liver fibrosis in a mouse model.
Methods Two-day-old C57BL/6 mice were injected with
streptozotocin and fed a high-fat diet from Week 4 after
birth. At Week 6 post-birth, lecinoxoids VB-201 or VB-
703 were given orally, once daily, for 3 weeks. Telmisartan
was administered orally, once daily, for 3 weeks, as posi-
tive control. At experiment conclusion, biochemical indi-
ces were evaluated. HE stain and quantitative PCR were
used to determine the extent of steatosis and steatohepati-
tis, and Sirius red stain was used to assess liver fibrosis.
Results Treatment with lecinoxoids did not alter the
concentration of blood glucose, liver triglycerides, or
steatosis compared with solvent-treated mice. However,
whereas VB-201 inhibited the development of fibrosis and,
to some extent, liver inflammation, VB-703 significantly
lessened both liver inflammation and fibrosis.
Conclusions This study indicates that using lecinoxoids
to antagonize TLR-2, and more prominently TLR-4, is
sufficient to significantly inhibit nonalcoholic steatohep-
atitis and liver fibrosis. Inhibiting monocyte migration with
lecinoxoids that are relatively weak TLR-4 antagonists
may alter liver fibrosis and to some extent nonalcoholic
steatohepatitis.
Keywords Nonalcoholic fatty liver disease  Toll-like
receptor  Nonalcoholic steatohepatitis  Lecinoxoids 
Fibrosis
Introduction
One of the major complications ensuing insulin resistance
and metabolic syndrome is nonalcoholic fatty liver disease
(NAFLD), which can progress from fatty liver (steatosis) to
fatty liver with inflammation (steatohepatitis) and liver
fibrosis. While the majority of subjects do not progress
beyond steatosis, it is not clear why others continue to
develop steatohepatitis. Supporting evidence suggests that
modulations in gut microbiota can be central to the disease
pathogenesis. In this context, it was shown that the integrity
of the small intestine is impaired in patients with NAFLD
and that the variety and proportion of gut flora in nonalco-
holic steatohepatitis (NASH) patients are altered compared
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with healthy controls [1, 2]. This microbiota dysbiosis can
promote NASH by increasing the levels of methylamines
and alcohol [3, 4], compounds that induce liver inflamma-
tion and injury [5]. Alterations in gut microbiome were also
shown to promote NASH by affecting bile acid metabolism,
resulting in impaired FXR-driven signaling and conse-
quently advancing steatosis [6]. Finally, wild-type mice
demonstrated increased disease severity in a methionine–
choline-deficient diet-induced NASH model when co-
housed with mice with altered gut microbiota [7].
Bacterial components from residing gut microbiome such
as lipopolysaccharides (LPS) and peptidoglycans (PGN) can
travel through the portal vein into the liver and encounter
toll-like receptors (TLRs) [8]. TLRs are a family of recep-
tors imperative for the innate immune response against
microbial invasion. Two of the TLRs, TLR-2 and TLR-4,
recognize the bacterial products PGN and LPS, respectively
[9, 10]. The interaction between these TLRs and their cog-
nate agonists instigates a cascade of signals that include
downstream phosphorylation events, which culminate in the
secretion of pro-inflammatory cytokines such as IL-6, IL-
1b, and TNF-a. Several reports demonstrated the correlation
between TLR-2 and TLR-4 and NAFLD pathogenesis. In
TLR-2 KO mice, a lower rate of liver inflammation was
observed when fed with a choline-deficient amino acid-de-
ficient diet or high-fat diet [11, 12]. This decrease was
manifested by a reduced number of macrophages and the
expression of pro-inflammatory cytokines in the liver
compared with wild-type mice. In addition, TLR-2 KOmice
also exhibited lower rates of liver fibrosis [12]. Mice bearing
nonfunctional mutated TLR-4 or TLR-4-targeted genes that
were fed methionine–choline-deficient diets demonstrated
reduced liver expression of TNF-a and TGF-b together with
decreased liver content of collagen and a-SMA compared
with control mice [13, 14].
Liver-resident Kupffer cells and hepatic stellate cells
(HSC), which express TLR-2 and TLR-4, are central to the
development of steatohepatitis and fibrosis [15–17]. The
activation of TLR-2 and TLR-4 on Kupffer cells induces
the production of TNF-a, TGF-b, and IL-1b, which in turn
augment HSC activation. Combined with the direct TLR-4-
mediated activation of HSC, ligation of these TLRs pro-
motes fibrogenesis [8, 18]. The recruitment of circulating
monocytes into injured liver was also shown to be of
importance to the development of liver fibrosis. Indeed, in
the absence of circulating monocytes, such as in CCR2-
deficient mice, fibrosis following acute liver injury was
reduced, suggesting that monocyte-derived macrophages
promote liver fibrosis [19].
We showed previously that a synthetic small molecule
analog, VB-201, which belongs to the lecinoxoid family
(lecin for lecithin—i.e., phospholipid, and oxoid for oxi-
dized), directly binds to the CD14 and TLR-2 and
consequently antagonizes TLR-2- and TLR-4-induced
activation of monocytes, macrophages, and DCs [20].
Moreover, we demonstrated that VB-201 inhibits migration
of monocytes toward various chemokines. In vivo treat-
ment with VB-201 impaired migration of monocytes into
the aorta and decreased the size of the aortic plaque in an
atherosclerosis mouse model [21]. In the current report, we
investigated the effect of VB-201 treatment on the devel-
opment of NASH and liver fibrosis in a mouse model. In
addition, we used VB-703, an unreported lecinoxoid
designed in silico for improved efficacy, that does not
affect monocytes migration, but exhibits increased inhibi-
tion of TLR-4 over VB-201. The results demonstrate that




C57BL/6 mice (15-day-pregnant females) were obtained
from Japan SLC (Japan). All animals used in the study
were housed and cared for in accordance with the Japanese
Pharmacological Society Guidelines for Animal Use.
Tested Reagents
The bioactive compounds VB-201 [(R)-1-hexadecyl-2-(4-
carboxy)butyl-sn-glycero-3-phosphocholine] and VB-703
[1-(2-octyl)dodecyl-2-(40-carboxy)butyl-glycero-sn-3-phos-
phoric acid pyridiniumethyl ester] (Fig. 1) were synthesized
in VBL’s chemical laboratory (Or Yehuda, Israel). The
Fig. 1 Chemical structures of VB-201 and VB-703
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generation of VB-201 was described previously [20]. VB-
703 was synthesized from (S)-1-(2-octyl)dodecyl-2-(40-
carboxy)butyl-glycerol. The free acid was protected by
esterification and reacted with phosphorus oxychloride
followed by the addition of O-tosyl ethylene glycol. After
aqueous hydrolysis, 1-(2-octyl)dodecyl-2-(40-carboxy)butyl-
glycero-sn-3-phosphoric acid tosylethyl ester was obtained.
Heating of 1-(2-octyl)dodecyl-2-(40-carboxy)butyl-glycero-
sn-3-phosphoric acid tosylethyl ester in pyridine and
purification by chromatography over silica gel yielded 1-(2-
octyl)dodecyl-2-(40-carboxy)butyl-glycero-sn-3-phosphoric
acid pyridiniumethyl ester (VB-703). To prepare dosing
solutions, VB-201 and VB-703 were dissolved in the sol-
vent (0.5 % ethanol in PBS). Telmisartan (Micardis) was
purchased from Boehringer Ingelheim GmbH (Germany)
and was dissolved in pure water.
Isolation of Human Monocytes and In Vitro
Generation of Dendritic Cells
Venous blood samples were obtained from healthy male
donors in compliance with the Institutional Review Board
at the Sheba Medical Center, Ramat Gan, Israel. PBMCs
were isolated on Ficoll-Paque PLUS (GE Healthcare,
Uppsala, Sweden) using 50-ml Leucosep tubes (Greiner
Bio-One, Frickenhausen, Germany). Cells were washed in
PBS (Kibbutz Beit Haemek, Israel) and incubated at 4 C
for 15 min in a buffer containing PBS and 0.5 % bovine
serum albumin (BSA) with human CD14 microbeads
(Miltenyi Biotec, Bergisch Gladbach, Germany). To gen-
erate monocyte-derived DC (Mo-DC), CD14? monocytes
were counted, washed, and seeded (106/ml) in medium
containing RPMI-1640, L-glutamine, b-mercaptoethanol,
10 % FCS, sodium pyruvate, nonessential amino acids,
0.01 M HEPES, antibiotics (Penicillin, Streptomycin), and
50 ng/ml human GM-CSF and 20 ng/ml human IL-4 (both
from PeproTech Asia, Rehovot, Israel). Medium was
replaced every 2–3 days.
Western Blotting
Monocytes (106/ml) were pretreated for 20 min with VB-
201 or VB-703 followed by 15 min activation with the
TLR-4 agonist LPS (100 ng/ml) (Sigma) or the TLR-2
agonist PGN (10 lg/ml) (InvivoGen). Cells were washed
and resuspended in lysis buffer containing 1:100 dithio-
threitol (DTT), phosphatase, and protease inhibitors
(Thermo Scientific). Samples were loaded onto a precast
Criterion TGX gel (Bio-Rad, Hemel Hempstead, UK) and
transferred onto nitrocellulose membrane. Blots were
blocked with 5 % milk or BSA in tris-buffered saline and
Tween 20 (TBST) for 1 h, followed by incubation with
primary and secondary antibodies. Membranes were
developed using an ECL kit (Thermo Scientific). The fol-
lowing antibodies were used for immunoblotting.
Primary Antibodies
p-p38 (cat. no. 4511; 1:1000) and p-IKK (cat. no. 2697;
1:1000) from Cell Signaling Technology (Danvers, MA,
USA); tubulin (cat.no. T9026; 1:5000) and p-ERK (cat. no.
M8159; 1:10 000) from Sigma (Israel); and heat shock
protein (HSP) 90 (cat. no. 13119; 1:500) from Santa Cruz
Biotechnology (Santa Cruz, CA, USA) were used as pri-
mary antibodies.
Secondary Antibodies
HRP donkey anti-rabbit (1:5000) and HRP goat anti-mouse
(1:3000) from Jackson ImmunoResearch (West Grove, PA,
USA) were used as secondary antibodies.
ELISA
To measure the effect of VB-201 and VB-703 on IL-12/
23p40 and IL-6 production, cells were collected 5–6 days
post-culture, counted, and seeded (106/ml). Cells were
pretreated for 1 h with VB-201 or VB-703 followed by
24-h activation with 100 ng/ml LPS to induce cytokine
production. IL-12/23p40 and IL-6 concentration in super-
natant was measured by ELISA. Cells activated with sol-
vent (0.5 % ethanol in PBS) were used as control.
In Vitro Cell Migration Assay
Human monocytes were pre-incubated for 20 min with
solvent (0.5 % ethanol/PBS), VB-201, or VB-703 as indi-
cated. RANTES (100 ng/ml) and MCP-1 (100 ng/ml) were
dissolved in 0.5 % FBS/RPMI-1640 and placed in the
lower chamber of a QCM 24-well migration assay plate
(Corning Costar; 5-mm pores). Migration assay was con-
ducted by seeding 300,000 treated cells in the upper
chamber, followed by incubation for 3 h. The number of
cells that migrated into the medium in the lower com-
partment was determined by flow cytometry (BD
FACSCalibur).
Induction of NASH and Treatment
In humans, diabetes mellitus is a risk factor for liver
fibrosis, which in some cases may culminate in hepato-
cellular carcinoma; NASH is critical to the link between
diabetes and liver fibrosis. The NASH model used in this
study, which enables to assess the histopathological events
that lead from diabetes to liver fibrosis, was induced in
C57BL/6 male mice (Japan SLC Inc) by a single
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subcutaneous injection of 200 lg streptozotocin solution
(STZ, Sigma-Aldrich, USA) two days after birth and a
high-fat diet (HFD, 57 kcal% fat, cat# HFD32, CLEA
Japan, Japan) after 4 weeks of age. The injection of STZ
induces inflammation in pancreatic islets that drives b-cell
injury, leading to diabetic conditions. The subsequent,
high-fat diet promotes liver steatosis and the recruitment
and activation of macrophages in the liver, similar to what
is seen in human NASH. At Week 6, after steatosis was
established, solvent (n = 8), VB-201 (n = 8), VB-703
(n = 8), or telmisartan (n = 8) were administered by oral
gavage from Week 6 for three more weeks. VB-201 and
VB-703 were given at a dose of 4 mg/kg once daily.
Telmisartan, which attenuates steatohepatitis progression,
was administered at a dose of 10 mg/kg once daily and
used as positive control. Normal mice (n = 5) were fed a
normal diet without any treatment until 9 weeks of age.
Measurement of Whole Blood and Plasma
Biochemistry
Nonfasting blood glucose was measured in whole blood
using LIFE CHECK (EIDIA, Japan). For plasma bio-
chemistry, blood was collected in polypropylene tubes
containing anticoagulant (Novo-Heparin, Mochida Phar-
maceutical, Japan) and centrifuged at 10009g for 15 min
at 4 C. The supernatant was collected and stored at
-80 C until use. Plasma alanine transaminase (ALT)
levels were measured by FUJI DRI-CHEM 7000 (Fujifilm,
Japan).
Measurement of Liver Triglyceride Content
Liver total lipid extracts were obtained by Folch’s method
[22]. Liver samples were homogenized in chloroform–
methanol (2:1, v/v) and incubated overnight at room tem-
perature. After washing with chloroform–methanol–water
(8:4:3, v/v/v), the extracts were evaporated to dryness and
dissolved in isopropanol. Liver triglyceride contents were
measured by Triglyceride E-test (Wako Pure Chemical
Industries, Japan).
Diagnosis and Scoring of Steatosis, NASH, and Liver
Fibrosis
The expression level of inflammation mediators associated
with steatohepatitis was used to determine NASH severity.
To that end, RNA was prepared from livers using RNeasy
mini kit (Qiagen). For cDNA preparation, 2 lg of RNA
was mixed with qScript reaction mix and qScript reverse
transcriptase (Quanta BioSciences) for 5 min at 22 C and
then for 30 min at 42 C. Reaction was completed by
incubating for an additional 5 min at 85 C. All real-time
PCR were performed using the 7300 Real-Time PCR
System (Applied Biosystems). Q-PCR was performed with
sets of probes with primers for mouse IL-1b, IL-6, IL-12/
23p40, and MCP-1 (Applied Biosystems). GAPDH was
used to normalize RNA levels. To assess steatosis and liver
fibrosis, sections were cut from paraffin blocks of liver
tissue prefixed in Bouin’s solution (Wako Pure Chemical
Industries). Steatosis score was calculated according to the
criteria of Kleiner [23]. Coverage of collagen deposition in
the liver was used as a marker to evaluate extent of fibrosis.
To visualize collagen deposition, Bouin’s fixed liver sec-
tions were stained using picro-Sirius red solution (Wal-
deck, Germany). For quantitative analysis, bright field
images of Sirius red-stained sections were captured around
the central vein using a digital camera (DFC280; Leica,
Germany) at a 200-fold magnification, and the positive
areas in five fields/section were measured using ImageJ
software (National Institute of Health, USA).
Statistical Analyses
Statistical analyses for in vivo studies were performed
using Bonferroni’s multiple comparison test on GraphPad
Prism 4 (GraphPad Software, USA). p values\0.05 were
considered statistically significant. A trend or tendency was
assumed when a one-tailed t test returned p values\0.05.
Results were expressed as mean ± SD. Student’s t test was
performed for the in vitro studies. p values B0.05 were
considered statistically significant.
Results
Effect of Lecinoxoids on TLR-2 and TLR-4
Activation and on Chemokine-Induced Migration
We first compared the inhibitory effect of VB-201 on TLR-
2- and TLR-4-mediated activation and chemokine-induced
migration of human monocytes to its derivative VB-703.
The results demonstrate that VB-703 inhibits TLR-4-medi-
ated signaling events and cytokine production with a pro-
foundly higher degree of activity than VB-201 (Fig. 2a, b)
but similar to VB-201’s inhibitory effect on TLR-2-medi-
ated phosphorylation (Fig. 2c). Moreover, VB-703 showed
annulled activity in the case of monocyte migration
(Fig. 2d).
Effect of Lecinoxoids Treatment
on Pathophysiological Characteristics of NASH-
Induced Mice
Next, we assessed the effect of VB-201 and VB-703 on the
development of steatosis, steatohepatitis and liver fibrosis
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in a NASH mouse model, using telmisartan as standard of
care. Mean body weight of the solvent group at experiment
conclusion was lower than that of the normal group. Mean
body weight of the telmisartan group was significantly
lower than that of the solvent group. No significant dif-
ferences were observed in mean body weight between the
solvent or the telmisartan group and the groups treated with
VB-201 or VB-703. Nevertheless, the solvent group
exhibited a significant increase in mean liver weight
compared with the normal group. The telmisartan group
showed a significant decrease in mean liver weight com-
pared with the solvent group. There were no significant
differences in mean liver weight between the solvent group
and the groups treated with VB-201 or VB-703.
Fig. 2 VB-201 and VB-703 differentially affect TLR-4-mediated
activation and migration of myeloid cells. Human monocytes (a,
c) and human monocyte-derived dendritic cells (b) were pretreated at
the indicated VB-201 or VB-703 concentrations (lg/ml) for 20 min
and then activated with (a, b) TLR-4 or (c) TLR-2 agonists LPS and
PGN, respectively. Samples were analyzed by Western blots and
ELISA for inhibition of downstream phosphorylation event and
cytokine production. Tubulin or HSP 90 was used in Western blotting
for loading control. One out of at least three experiments is shown.
For b, data are mean ± SD from triplicates. *p\ 0.001 versus
solvent; **p\ 0.001 versus solvent and VB-201 (d) Human mono-
cytes were pre-incubated for 20 min with solvent, VB-201, or VB-
703 at the indicated concentrations (lg/ml) and then seeded in the
upper part of a trans-well migration assay plate. RANTES (100 ng/
ml) and MCP-1 (100 ng/ml) were placed in the lower chamber of the
wells for 3 h. The number of cells that migrated into the medium in
the lower compartment was determined by flow cytometry (BD
FACSCalibur). *p\ 0.05 versus solvent. Data are mean ± SD from
triplicates, normalized to solvent-treated cells. One out three exper-
iments is shown
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Furthermore, we found that solvent-treated mice had ele-
vated blood glucose and plasma ALT levels, and that
treatment with lecinoxoids or telmisartan did not affect
these parameters. Next, we sought to determine whether
lecinoxoids can decrease liver fat content in NAFLD. The
results show that solvent-treated mice had significantly
increased liver triglyceride content compared with the
normal group, and that while telmisartan treatment
Table 1 Effect of treatment regiments on pathophysiological characteristics of NASH-induced mice
Normal Solvent VB-201 VB-703 Telmisartan
Body weight (g) 21.32 ± 0.10 18.77 ± 0.70 18.15 ± 0.70 18.74 ± 0.96 15.2 ± 0.63*
Liver weight (mg) 844.20 ± 45.77 1267.37 ± 37.33a 1366.75 ± 79.98 1341.00 ± 66.05 986.38 ± 46.48*
Whole blood glucose (mg/dL) 144.20 ± 9.35 709.00 ± 58.34a 628.62 ± 42.25 648.70 ± 40.06 751.00 ± 55.28
Plasma ALT (U/L) 21.20 ± 5.31 62.00 ± 20.95 41.00 ± 5.40 32.60 ± 3.36 34.25 ± 2.90
Liver Tg (mg/g liver) 1.98 ± 0.20 38.27 ± 5.15a 40.02 ± 4.27 31.20 ± 3.07 12.48 ± 1.54**
Steatosis score 0 1.25 ± 0.20 1.00 ± 0.19 1.00 ± 0.31 0.25 ± 0.16**
All data presented as mean ± SD. Normal n = 5, solvent n = 8, VB-201 n = 8, VB-703 n = 8, telmisartan n = 8
* p\ 0.01 telmisartan versus solvent
** p\ 0.001 telmisartan versus solvent
a p\ 0.001 solvent versus normal
Fig. 3 VB-703 inhibits steatohepatitis. Mice were induced for
NASH, and the indicated compounds were administered orally at a
dose of 4 mg/kg once daily from Week 6 to Week 9. Telmisartan was
administered at a dose of 10 mg/kg once daily. Q-PCR was performed
on RNA extracted from livers of mice on Week 9 to detect IL-1b (a),
IL-6 (b), MCP-1 (c), and IL-12/23p40 (d). GAPDH was used to
normalize RNA levels. Normal n = 4, solvent n = 7-8, VB-201
n = 7–8, VB-703 n = 8, telmisartan n = 5–6. Data are mean ± SE
from triplicates. *p B 0.05
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significantly decreases liver triglycerides, the administra-
tion of lecinoxoids had no apparent effect (Table 1). In
accord with the latter result, telmisartan significantly
reduced steatosis, whereas treatment with lecinoxoids had
no effect on steatosis (Table 1).
VB-201 and VB-703 Effect on Steatohepatitis
We now examined the effect of each of the lecinoxoids on
NASH, where NASH is defined as increased expression
levels of inflammation mediators in the liver compared
with normal mice. For that, upon killing, RNA was pre-
pared from livers and the differences between tested groups
in the expression of inflammation mediators associated
with steatohepatitis were determined by quantitative PCR.
Analysis of inflammation mediators IL-1b, IL-6, MCP-1,
and IL-12/23p40 in the liver of NASH-induced mice
showed that VB-703 for the most part significantly inhib-
ited expression of pro-inflammatory mediators, whereas
VB-201 significantly attenuated only the expression of IL-
12/23p40 (Figs. 3a–d).
Lecinoxoids Restrict Liver Fibrosis
In order to evaluate whether treatment with lecinoxoids
restricts liver fibrosis, liver samples were stained with
Fig. 4 VB-201, and more profoundly VB-703, restricts liver fibrosis.
Mice were induced for NASH, and the indicated compounds were
administered orally at a dose of 4 mg/kg once daily from Week 6 to
Week 9. Telmisartan was administered at a dose of 10 mg/kg once
daily. Liver sections prepared at the end of the experiment were
stained with picro-Sirius red to visualize collagen deposition.
a Representative stain of each group is shown. b Percent of fibrosis
for each tested group. Normal n = 5, solvent n = 8, VB-201 n = 8,
VB-703 n = 8, telmisartan n = 6. Data are mean ± SE. *p B 0.05,
**p\ 0.001. One out of two experiments is shown
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Sirius red to assess collagen content, as a marker for the
presence of fibrogenesis. The extent of fibrosis was deter-
mined by calculating the percent of positively stained area
in five fields within a section. The results, presented in
Fig. 4a, b, demonstrate that VB-703, more than VB-201
and even telmisartan, significantly restricted the develop-
ment of liver fibrosis.
Discussion
NAFLD is a progressive disease that begins with a fatty
liver and that, if left untreated, may advance to liver
inflammation and in few cases might culminate in liver
fibrosis. The majority of drugs currently tested in clinical
trials focus on targeting molecules that are involved in the
regulation of lipid and glucose metabolism. These drugs
include agonists of nuclear receptors, such as FXR and
PPAR-a that induce anti-steatotic responses in NASH
patients [24], a niacin analog that reduces triglycerides
levels, and a glucagon-like peptide-1 receptor agonist that
induces insulin secretion. In this study, we evaluated an
alternative approach according to which oxidized phos-
pholipid small molecules are used to target pathways
directly associated with liver inflammation and fibrosis for
treating NASH and ensuing liver fibrosis. Two major stages
were suggested to promote NASH and liver scarring: the
recruitment of circulating monocytes into the fatty liver and
activation of these monocytes, together with resident
Kupffer and stellate cells, through TLR-2 and TLR-4. In
virtue of the biological function of the lecinoxoids, treat-
ment of mice with VB-201 or VB-703 did not alter steatosis.
However, when indices directly associated with inflamma-
tion and fibrosis were analyzed, differences in the efficacies
of VB-201 and VB-703 were revealed. Functionally, VB-
201 differs from VB-703 in its ability to also inhibit
monocytes migration, but it is a weaker antagonist of TLR-4
than is VB-703. Nevertheless, our results demonstrate that
significant effects of lecinoxoids on liver inflammation
could be attained by targeting TLR-2 and predominantly
TLR-4, since VB-703 was superior to VB-201 in inhibiting
all of the inflammation mediators tested. Although VB-201
showed a weaker influence than VB-703 on steatohepatitis,
these results do not exclude the therapeutic role VB-201
may have on fibrosis. Indeed, limiting monocytes migration
to ameliorate liver fibrosis has already been shown with
cenicriviroc mesylate, a CCR2 and CCR5 antagonist, which
reduced fibrosis by 50–65 % both in a rat thioacetamide
model and in a mouse NASH model and is currently
undergoing evaluation in a phase II clinical study in patients
with liver fibrosis. Future efficacy studies either in animal
models or in clinical practice should therefore include test
compounds that are preferentially strong antagonists to
TLR-4 or combination therapies to decrease monocytes
migration and TLR-4 activation to treat both steatohepatitis
and liver fibrosis. In this study, we did not test the effect of
VB-201 and VB-703 at the cellular level, in the sense that
hepatic cells involved in NASH and liver fibrosis such as
HSC and Kupffer cells were not isolated and analyzed for
their response in the presence of VB-201 and VB-703.
Moreover, in this model, the extent of fibrosis reached in the
control group was relatively low. Accordingly, in vitro
studies are currently underway to test the effect of these and
other lecinoxoids on pure resident liver macrophages and
HSC, alongside in vivo experiments in other liver fibrosis
models. To conclude, small molecules oxidized phospho-
lipids that strongly antagonize TLR-4 and inhibit mono-
cytes migration should be further explored for their
potential to treat subjects with NASH and liver fibrosis.
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